These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3588382)

  • 1. [Effect of long-term treatment with fenofibrate on serum lipids and lipoproteins in patients with hypercholesterolemia and hypertriglyceridemia].
    Sznajderman M
    Pol Tyg Lek; 1986 Dec 22-29; 41(51-52):1633-7. PubMed ID: 3588382
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of procetofen on serum lipids and apoproteins.
    Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
    Ivanova TN; Poliakova ED; Olfer'ev AM; Perova NV
    Biull Eksp Biol Med; 1998 May; 125(5):569-73. PubMed ID: 9644562
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of the lipid-lowering agent, procetofen, on the makeup of human biliary lipids].
    Grandjean EM; Mordasini R; Paumgartner G
    Schweiz Med Wochenschr; 1979 Apr; 109(16):601-2. PubMed ID: 219470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia.
    Lehtonen A; Viikari J
    Artery; 1982; 10(5):353-67. PubMed ID: 7181678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of cinnarizine in hyperlipaemic patients.
    Saba P; Galeone F; Salvadorini F; Guarguaglini M; Houben JL
    G Clin Med; 1974 Aug; 55(8):586-99. PubMed ID: 4377134
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic trial of simvastatin versus fenofibrate in primary hypercholesterolemia].
    Turki S; Mekaouer A; Kaabachi A; Ftouhi B; Mebazaa R; Ben Khalifa F
    Tunis Med; 1994 Nov; 72(11):619-24. PubMed ID: 7762089
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of combined treatment with lovastatin and colestipol on serum lipids and lipoproteins].
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB
    Wiad Lek; 1993 Aug; 46(15-16):581-5. PubMed ID: 7975581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of micronized phenofibrate on the lipoproteins of the blood plasma at different initial lipid levels].
    Perova NV; Ozerova IN; Kalinina AM; Pavlova LI; Olfer'ev AM; Mel'kina OE; Golubev MA; Oganov RG
    Ter Arkh; 1996; 68(1):71-6. PubMed ID: 8644040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypolipemic effects of a new tetralin derivative: compound 13473-Su (Ciba)].
    Ciobanu V; Zălaru MC; Ciocan A; Mihăilescu S
    Stud Cercet Med Interna; 1971; 12(1):67-80. PubMed ID: 5565781
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.